Company: PRME
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001628280-25-018704
Chunk: 13

Company: Prime Medicine, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 13
---
 |
| Robert Nelsen              |     |  61 |     | Director (Class III) |
| Michael Kelly              |     |  68 |     | Director (Class I)   |
| David Schenkein, M.D.      |     |  67 |     | Director (Class I)   |
| Wendy Chung, M.D., Ph.D.   |     |  56 |     | Director (Class II)  |
| Kaye Foster                |     |  65 |     | Director (Class II)  |
| Keith Gottesdiener, M.D.   |     |  71 |     | Director (Class II)  |
| Jeffrey Marrazzo           |     |  46 |     | Director (Class II)  |

#### Nominees for Election as Class III Directors

#### Thomas Cahill, M.D., Ph.D.
has served as a member of our board of directors since November 2021. Dr. Cahill is the Founder and has served as the Managing Partner of Newpath Partners, a Boston-based life science venture fund focused on therapeutic companies, since October 2018. Dr. Cahill is the founding investor and director of nChroma Bio, Inc., Exo Therapeutics, Inc., Kisbee Therapeutics, Inc., Magnet Biomedicine, Inc., Myeloid Therapeutics, Inc., Convergence Bio, Inc., Autobahn Therapeutics, Inc., Leal Therapeutics, Inc. and Amplitude Therapeutics , Inc. Prior to Newpath Partners, Dr. Cahill served as an Advisor at Raptor Group Holdings, where he helped further establish and lead the life science and technology investment portfolio, from September 2016 to May 2018. Dr. Cahill received both his M.D. and Ph.D. from Duke University and his M.S. from Stanford University.

We believe that Dr. Cahill is qualified to serve on our Board of Directors based on his experience in the medical and venture capital industries.

#### Robert Nelsen
has served as a member of our board of directors since September 2020. Mr. Nelsen co-founded ARCH Venture Partners, L.P., a venture capital firm focused on early-stage technology companies, in 1986 and has served as a Managing Director of ARCH Venture Partners or its affiliated entities since 1994. Mr. Nelsen currently serves on the board of directors of Vir Biotechnology, Inc., Sana Biotechnology, Inc., Lyell